Global Expansion MERIT CRO's Australia expansion creates a regional gateway to win CRO and sponsor outsourcing deals in the APAC market, complementing its global endpoint capabilities. This footprint can be leveraged to propose fast onboarding, local regulatory support, and seamless transition from preclinical to clinical work for multi-country trials.

Credible Track Record MERIT CRO's track record delivering endpoint expertise to many of the world's leading pharma companies provides a credible reference for winning larger, multi-region studies. Use these success stories to engage CROs and sponsors seeking reliable endpoints, scalable solutions, and personalized service.

End-to-End Integration The OSOD acquisition enables preclinical capabilities, turning MERIT into an end-to-end partner from preclinical to clinical endpoints, reducing handoffs and accelerating timelines for sponsors aiming to streamline development and maintain consistency across phases.

Funding Partnerships The Mianus Clarity Fund and related partnerships suggest a financing and ecosystem-driven angle for sales conversations, enabling sponsors to advance programs with strong endpoint capabilities even when upfront funding is a constraint.

Leadership Growth Leadership momentum and sustained recognition, including a COO appointment and Inc. 5000 accolades, signal scalable operations and governance that resonate with mid-market sponsors looking for a dependable, growth-oriented endpoint partner.